Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia

Oncotarget

Volumn 7, Issue 38, 2016, Pages 61069-61080

  Qin, Lei ^a,b   Dominguez, Donye ^b   Chen, Siqi ^b   Fan, Jie ^b   Long, Alan ^b   Zhang, Minghui ^a,b   Fang, Deyu ^b   Zhang, Yi ^a   Kuzel, Timothy M ^b   Zhang, Bin ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AML; CD8+ T cells; IL 33; ST2; Tolerance

Indexed keywords

ANTILEUKEMIC AGENT; RECOMBINANT INTERLEUKIN 33; UNCLASSIFIED DRUG; GAMMA INTERFERON; IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFECT; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; OVERALL SURVIVAL; SURVIVAL RATE; T LYMPHOCYTE; ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTATION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; IMMUNOTHERAPY; METABOLISM; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELLS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84992519098     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11179     Document Type: Article

References (40)

1. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002; 100:2132-2137.
2. Greiner J, Bullinger L, Guinn BA, Dohner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res. 2008; 14:7161-7166.
3. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012; 26:2186-2196.
4. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia. 2014; 28:1784-1792.
5. Curran E, Corrales L, Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol. 2015; 5:83.
6. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013; 123:1999-2010.
7. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998; 95:1178-1183.
8. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI. Crosspresentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001; 98:1070-1077.
9. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlen C, Greenberg PD. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006; 12:335-341.
10. Chen X, Kline DE, Kline J. Peripheral T-cell tolerance in hosts with acute myeloid leukemia. Oncoimmunology. 2013; 2:e25445.
11. Schmitz J, Owyang A, Oldham E, Song YL, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin JZ, Li XX, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23:479-490.
12. Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. Immunity. 2015; 42:1005-1019.
13. Lloyd CM. IL-33 family members and asthma-bridging innate and adaptive immune responses. Curr Opin Immunol 2010; 22:800-806.
14. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, Nakanishi K, Yamanishi K. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA. 2013; 110:13921-13926.
15. Pushparaj PN, Tay HK, H'Ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009; 106:9773-9778.
16. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie ANJ. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464:1367-U1369.
17. Miller AM, Xu D, Asquith DL, Denby L, Li YB, Sattar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008; 205:339-346.
18. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, Zhang X, Finn OJ, Chen X, Lu B. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol. 2011; 41:3351-3360.
19. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, Klemenz R, Nakae S, Adler H, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science. 2012; 335:984-989.
20. Gao K, Li X, Zhang L, Bai L, Dong W, Gao K, Shi G, Xia X, Wu L, Zhang L. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013; 335:463-471.
21. Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F, Jiang J, Wu C, Zhang X, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015; 194:438-445.
22. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014; 74:1789-1800.
23. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014; 31:31-37.
24. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009; 114:1545-1552.
25. Kline DEFD, Chen X, Kline J. CD8a+ dendritic cells dictate immune responses against murine AML. J ImmunoTherapy Cancer. 2013; 1:P158.
26. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014; 65:185-202.
27. Bryan LJ, Gordon LI. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies. Oncology. 2015; 29:431-439.
28. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015; 112:1501-1509.
29. Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J. 2014; 92:195-203.
30. Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, Chomel JC, Turhan A, Guilhot F, et al. BCR-ABLinduced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res. 2014; 74:2669-2676.
31. Mager LF, Riether C, Schurch CM, Banz Y, Wasmer MH, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015; 125:2579-2591.
32. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, Koehn BH, Pfeifer D, Taylor PA, Prinz G, Dierbach H, Stickel N, Beck Y, et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015; 125:3183-3192.
33. Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I, Paczesny S. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015; 7:308ra160.
34. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009; 123:1047-1054.
35. Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol. 2011; 41:1675-1686.
36. Xiao P, Wan XP, Cui BJ, Liu Y, Qiu CY, Rong JB, Zheng MZ, Song YJ, Chen LQ, He J, Tan QC, Wang XJ, Shao XY, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloidderived suppressor cells. Oncoimmunology. 2016; 5.
37. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117:4501-4510.
38. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010; 116:2484-2493.
39. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, Fauci AS. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008; 181:6738-6746.
40. Chen SQ, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang DY, Kuzel TM, Zhang B. Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell-Dependent Mechanism. Cancer Res. 2015; 75:519-531.